Precision Medicine

A $520K state grant will provide firefighters with a new AI-powered blood test, highlighting a major push to protect high-risk first responders.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

The successful launch of rosacea treatment Emrosi™ generated $14.7M, driving Journey Medical's revenue to $61.9M and signaling a major strategic win.

A new high-tech wellness center arrives in Boulder, offering cutting-edge services. But does the science support the high price of proactive health?

Aerin Medical's milestone highlights a major shift toward minimally invasive, in-office treatments for chronic nasal issues, moving beyond traditional surgery.

A new FDA-cleared device uses water vapor to ablate prostate tissue, showing high efficacy in trials while minimizing life-altering side effects.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

Health Canada greenlights MeMed's rapid diagnostic tool, a major step in the nation's fight against deadly sepsis and growing antimicrobial resistance.

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

As oncologists warn of supplement risks, one company founded by a doctor and caregiver aims to provide a safer, transparent path for cancer survivors.